On August 7, INNOVENT BIO rose 3.02% in regular trading, trading at HK$93.7/share, with turnover of HK$1.082 billion.

On the news front, the company recently disclosed first-half product revenue exceeding RMB 8.2 billion, up over 55% year-over-year, with second-quarter product revenue surpassing RMB 4.3 billion, representing approximately 60% growth and significantly beating market expectations. Goldman Sachs raised its target price to HK$111.68 using a DCF model, citing accelerating commercialization momentum. BOCOM International set a target of HK$118, noting increased certainty of the company's RMB 20 billion mainland revenue target for next year. Citi reiterated its HK$115 target, naming INNOVENT BIO a top pick in the China biotech sector. All three maintained Buy ratings.

Additionally, the company announced the first patient dosing in a pivotal registration study evaluating Ibi363 combined with bevacizumab for advanced colorectal cancer, marking a significant milestone in its oncology immunotherapy pipeline. The convergence of strong commercial execution and continued R&D catalysts supported the stock's upward momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)